Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Netarsudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 19/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 6/20 | 1.00 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netarsudil SCHEMBL114266 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29351219 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL21679903 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29478436 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16036278 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL16037348 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL29677622 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113753 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL113752 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 | |
| Netarsudil SCHEMBL114348 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| EP-4527387-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2025-03-26 | — | — | EP | claimed |
| WO-2023221852-A1 | COMPOUND PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA AND USE THEREOF | 沈阳药科大学 | 2023-11-23 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4655392-A2 | METHODS FOR SELECTING CULTURED CORNEAL ENDOTHELIAL CELLS | Universiteit Maastricht (NL) | 2025-12-03 | — | — | EP | disclosed |
| EP-4463439-A1 | SYNTHETIC INTERMEDIATES AND IMPROVED PROCESSES FOR PREPARING ROCK INHIBITORS | Alcon Inc. (CH) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024158290-A2 | METHODS FOR SELECTING CULTURED CORNEAL ENDOTHELIAL CELLS | UNIVERSITEIT MAASTRICHT (NL) | 2024-08-02 | — | — | WO | disclosed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023136942-A1 | SYNTHETIC INTERMEDIATES AND IMPROVED PROCESSES FOR PREPARING ROCK INHIBITORS | AERIE PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| JP-2022160467-A | PHARMACEUTICAL PRODUCT 2 | 興和株式会社 | 2022-10-19 | — | — | JP | disclosed |
| US-20220304995-A1 | OPHTHALMIC COMPOSITIONS | ALCON INC. (CH) | 2022-09-29 | — | — | US | disclosed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | Micro Labs Ltd. (IN) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | PTGIR, ADRB1, ADRB2 | ROCK2 180/4885ROCK1 67/4885MYLK4 122/4885 |
| US-11345664-B2 | Process for the preparation of (S)-Netarsudil,its salts and polymorphs | VKORC1L1, CYP3A4, REN | ROCK2 165/4885ROCK1 52/4885MYLK4 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.